Trump, 79, Admits He Should ‘Probably’ Take Weight Loss Drugs
Mike Stobe/Getty Images President Donald Trump admitted he “probably” should be on the “fat drug.” Trump, 79, got quizzed about his use of GLP-1 drugs such as Wegovy and Ozempic in a two-hour sitdown with The New York Times on Wednesday. Asked whether he had ever used the popular drugs for diabetes and weight loss, […]
Trump Tells NYT He “Probably Should Take Fat Drug”
The Daily Beast reports: Trump admitted he “probably” should be on the “fat drug.” Trump, 79, got quizzed about his use of GLP-1 drugs such as Wegovy and Ozempic in a two-hour sitdown with The New York Times. Asked whether he had ever used the popular drugs for diabetes and weight loss, Trump replied, “No, […]
5 payer CEOs to testify before Congress on rising healthcare costs
House Republicans have asked the leaders of some of the nation’s largest health insurers to testify before Congress at the end of January as scrutiny intensifies over rising healthcare costs and industry profits. On Jan. 22, the CEOs of UnitedHealth Group, CVS Health, Elevance Health, The Cigna Group, and Ascendium (parent company of Blue Shield […]
More than a quarter of adults worldwide could benefit from GLP-1 medications for weight loss, study finds
The worldwide prevalence of obesity has more than doubled in the last three decades, bringing with it an increase in weight-related diseases like diabetes, cardiovascular disease, and cancers. This public health crisis strains global health care systems and economies, but a new study co-led by investigators from Mass General Brigham could inform strategic programs to […]
Medifast Shifts to Metabolic Health: A Durable Growth Path?
Medifast, Inc. MED is moving beyond its traditional identity as a weight-loss company to establish itself as a leader in the expanding metabolic health market. The company highlighted a significant opportunity to deliver a reset aimed at improving metabolic health. With more than 90% of U.S. adults considered metabolically unhealthy, this issue represents both a […]
Many regain weight after stopping GLP-1 drugs, data shows. Here’s why
People on average regain weight at a rate of 0.4 kg/month after they stopped taking their weight loss medications, a review of 63 trials covering over 9,000 individuals showed.
Kallyope eyes clinic with K-554 for obesity
Kallyope Inc. has outlined plans to initiate phase I studies this year with K-554, a non-incretin peptide candidate offering a new mechanism of action in obesity.
7 CES 2026 technologies that made science fiction feel uncomfortably practical
CES 2026 had no shortage of AI products, but a quieter pattern stood out across booths that had little else in common. Some of the most attention-grabbing technologies weren’t built for screens or productivity dashboards. They were built to be eerily close to us, and for personal spaces like bathrooms, bedrooms, desks, and even the […]
STAT+: Eli Lilly’s Zepbound, on top of immunology drug, helped reduce psoriatic arthritis symptoms
Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese patients with an autoimmune condition that causes joint pain more than Taltz did alone. The data suggest the GLP-1 drug Zepbound, which has already been shown to help with obesity and sleep apnea, among other […]
New Lilly data suggest Zepbound boosted effect of autoimmune drug
New Phase 3b data from Eli Lilly suggest that its blockbuster weight loss drug helped boost the efficacy of an autoimmune treatment in select patients with active psoriatic arthritis who were overweight or obese. …